Related Experiment Video
Updated: Jul 18, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins in heart failure. Beyond the lipid lowering effect
Dimitris Tousoulis1, Marietta Charakida, Elli Stefanadi
1Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, Greece. drtousoulis@hotmail.com
International Journal of Cardiology
|December 19, 2006
Summary
Statins offer potential benefits for heart failure (HF) patients by reducing myocardial hypertrophy and apoptosis. However, further large trials are needed to confirm their efficacy and safety in HF, considering potential negative impacts on cholesterol and ubiquinone levels.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Statins are widely used for hyperlipidemia and coronary heart disease.
- Beyond cholesterol reduction, statins possess pleiotropic effects including anti-inflammatory and antioxidant properties.
Purpose of the Study:
- To review the potential benefits and risks of statin use in heart failure (HF).
- To evaluate experimental and clinical evidence regarding statins' impact on HF pathophysiology and outcomes.
Main Methods:
- Review of experimental data on statin mechanisms in cardiac conditions.
- Analysis of small randomized trials and retrospective data from large statin trials concerning HF patients.
Main Results:
- Experimental evidence suggests statins may inhibit hypertrophy, reduce apoptosis, and oxidative stress in HF.
- Short-term trials indicate potential improvement in HF pathophysiology; retrospective analyses suggest long-term clinical benefits.
- Concerns exist regarding low cholesterol association with worse HF prognosis and statin-induced ubiquinone reduction.
Conclusions:
- Statins show promise in HF, but large prospective trials are essential to confirm cardiovascular outcome benefits.
- Further research is needed to elucidate mechanisms, optimal dosing, and drug interactions for statins in HF.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...